Analysis of TransThera Sciences’ YOCHANRA (Tinengotinib) Receives First Prescription in China – World’s First Approved Targeted Therapy for Post‑FGFR‑Inhibitor Cholangiocarcinoma - aVenture Research
Insight, China's Pharmaceutical Industry
TransThera Sciences’ YOCHANRA (Tinengotinib) Receives First Prescription in China – World’s First Approved Targeted Therapy for Post‑FGFR‑Inhibitor Cholangiocarcinoma
TransThera Sciences (Nanjing), Inc. (HKG: 2617) announced that the first nationwide prescription for its independently developed Class 1 innovative drug YOCHANRA® (tinengotinib tablets) was written on 17 Sep 2026 at Peking University Cancer Hospital, where Professor Zhou Jun of the Department of Gastrointestinal Oncology prescribed the drug to a patient with FGFR2 fusion/rearrangement advanced cholangiocarcinoma previously treated with systemic therapy and an FGFR inhibitor. The milestone marks